High precision Mylc cellschange the future of drug development
and research of infectious diseases!
(artificial human leukocytes)

You can evaluate the efficacy and safety, essential for the development of drugs and cosmetics more accurately,
efficiently and quickly at lower cost than ever. High precision human leukocytes stably supplied through cutting-edge
technologies will strongly drive the development of drugs and cosmetics and research of infectious diseases in future.

Mylc cells are:Mylc cells( immature dendritic cells)

Conventional dendritic cells
for experiments

Uniform differentiation stage
and highly homogeneous

Cells with different differentiation
stages are present

iPS cells/PBMCs

Human dendritic cells produced through regenerative medicine technology.
Controlled in an immature (non-stimulated) state ideal for various evaluations and researches.

Homogeneous blood cellswith identical genetic
information

We can control tothe optimum
differentiation stage

The same genetic information andconditions can be always reproduced
because they are produced in ourlaboratory. This feature contributes toa drastic improvement in the accuracy
and applicability of pharmaceuticalevaluation.

Differentiation stage (maturity )can be minutely controlled with
our high level of regenerative
medicine technologies andproduct control. Research andevaluation of high accuracy areavailable.

CFU-GM

CFU-M

Monoblast

Stablemass-production andsupply are possible
You can obtain blood cells in ideal
conditions any time. You can conduct
research and development andefficacy evaluation with no delay andaccelerate development.

Dendritic cell(Immature)

Monocytes

Production ofblood cells throughregenerative
medicine technology

Dendritic cell(Antigen presenting cell)

Stimulation

Mylc cells
Macrophage

Optimum differentiation state

Our products can be used in various evaluations of drugs and functional materials
such as food and cosmetics and drastically improve the reliability and speed.
Efficacy evaluation

Safety evaluation

Measuring cell response precisely,
we can efficiently facilitate the evaluation.

On various studies based on alternative methods to animal testing,
we can greatly reduce the time and cost.

By quantifying transmitters released from Mylc cells after theaddition of test compounds, cell responses can be concisely
measured with high precision. The cells with the same genetic
information can be used any time and the results are accurate
in sequential tests.
In addition, uMylc, with specific characteristics of diseases, isattracting attention as a promising pharmacological study
method. In many ways, high precision blood cells greatly
accelerate the development of pharmaceutical products.

In test methods based on alternative methods to animal testing, there used to bevarious challenges based on the differences between the cells used* and normal
human in vivo cells, such as low accuracy of results, high cost, and lengthy time.
MiCAN’s new method using only pure myeloid cells derived from iPS cells canquantify transmitters released by stimulation. This method drastically increases
the accuracy of test results and allows a wide variety of evaluation designs. The
time and cost for measurement are greatly reduced. This is an epoch-making
evaluation service contributing to fast production development.
*Cell lines represented by THP-1, Mono-Mac-6, etc.

Evaluation of drug effects and efficacy

Skin sensitization assay

We can measure the response of cells to drugs and functional materials withhigh precision. Speedy and reliable evaluation greatly accelerates thedevelopment of drugs and materials.

••

For the standard 10 compounds of the h-CLAT ( P1 – N10 ), similar
results to those in model cells (LLNA ) can be obtained. Time and cost
can be drastically reduced because our method is free from thetime-consuming procedures and confirmation required in the h-CLAT.

Pyrogen test
Our method shows similar sensitizing
property and stability to in vivo cells
compared with those using existing
cells (Mono-Mac-6 ).

Wide variety of evaluation designs are available• Want to accurately determine response patterns in people who have idiosyncrasies.
• Want to accurately evaluate and compare the effects of drugs under identical conditions.

Want to compare the degrees of responses to drugs in humans with sensitive skin.
Want to advance development of drugs quickly by measuring drug effect in each evaluation.

3 different types of the genetic backgrounds to meet demands.
You can select the base cells ( 3 types ) and genotype of white blood cells ( HLA, etc.).
You can also customize the cells from provided blood (uMylc ).

aMylc

iMylc

uMylc

Human peripheral blood mononuclear cells

iPS cell-derived blood cells

Customization using provided blood

Showing in vivo-like characteristics andreactions.

Having standardized genetic background.
Standard reactions can be elicited.

Blood cell materials with characteristics ofthe donor can be prepared.

Mylc's high sensitivity and accurate results
strongly drives research of infectious diseases.
Mylc strongly supports research with high sensitivity to infection and accurate results compared withconventional research materials.

Comparison of sensitivity to infection
Low sensitivity

High sensitivity

Density ofDengue virus IV

4000

800

160

326.4

1.3

0.26

0.05

0.01

0.002

0.0004

none

123456789101112aMylc

iMylc
Vero cell(monkey-derived)
K562cel(human leukemic cell line)

Our integrated technologies are the driving force behind our blood cells
development by regenerative technology.
Our advanced technology and experience are the essentials of our blood production.

Gene editing

Differentiation-inducing

technology

We can produce blood cells reflecting various
genetic backgrounds with genetic manipulation
technology of progenitor cells.

Cell immortalizatio
technology

We immor talize the cells just before each
shipment. Thus, they maintain the original
characteristics and can be used in experiments
in a fresh condition. Their characteristics are
hard to change unlike originally immortalized
leukemia cell lines, and you can obt ain results
similar to normal in vivo responses.

technology

Cell design capability

We p rovi d e hi g h - qu a li t y b l o o d c e ll s in a
homogeneous differentiation state from iPS stem
cells with a high differentiation inducing rate.

Cell design capability is our extraordinary corecompetence, unique to MiCAN.
We can design cells in a comprehensive mannerbased on various factors including selection of gene,
control of differentiation stage,and determination of the immortalization point.

technology

By improving the production efficiency, we
can provide the required number of blood cells
stably at a reasonable price.

MiCAN Technologies, Inc.

Evaluation and research in acommon laboratory with Kyoto University
Our headquarters and research laboratory are located in
Kyoto-University Katsura Venture Plaza, where Kyoto University
nurtures the creation of new businesses utilizing newideas/technologies and intellectual properties.

Consistent production

Kyoto-University Katsura Venture Plaza, 1-36, Goryo-ohara,
Kyoto Nishikyo-ku, Kyoto 615-8245, Japan
Kyoto-University Katsura Venture Plaza

Patent application for non-stimulated dendritic cells for research of viruses (Second product)
Adopted for the Economic Gardening Support Grant supported by Kyoto Industrial Support Organization 21
Certified as Management of Wisdom by the Kyoto Chamber of Commerce and Industry (2018)075-381-3008
http://micantechnologies.com
info@micantechnologies.com